Research at the University of Leeds and the Institute of Cancer Research in the UK shows that a therapeutic virus
injected into the bloodstream can target aggressive brain tumors.
Taken together, these studies demonstrate that a single therapeutic virus
, when controlled by the telomerase promoter, can effectively kill a wide variety of human cancer cell types and therefore potentially be used to treat many types of primary and metastatic cancers.
Mutations in the p53 tumor suppressor gene are present in over 50 percent of all human cancers and are the genetic abnormality targeted by Onyx's lead therapeutic virus